Salute e Benessere

Drug Repurposing Market Projected to Reach USD 47.8 Billion by 2034 with a CAGR…

This change in the size of the industry is attributed to a sluggish development of the sector. With several opportunities created for key players in the sector, the ecosystem is set to progress at a CAGR of 4.7% through 2034. This change in the size of the industry is attributed to a sluggish development of the sector. With several opportunities created for key players in the sector, the ecosystem is set to progress at a CAGR of 4.7% through 2034. With the elevated drug development...
PR Newswire
17/07/2024

Cholesterol Testing Products Market Worth US$ 49.4 Billion by 2034 | Exclusive…

With the growing proportion of obese population across the world, the rate of heart issues is growing. People have been struggling to ensure the well-being of the heart, which drives the demand for suitable measures to arrest such issues. With the growing proportion of obese population across the world, the rate of heart issues is growing. People have been struggling to ensure the well-being of the heart, which drives the demand for suitable measures to arrest such issues. The demand from...
PR Newswire
17/07/2024

Future of Central Nervous System Therapeutics Market Worth USD 231.8 Billion by…

The progress of the competitive landscape will help the market valuation reach USD 231.8 billion by 2034. The last recorded size of the industry was USD 102.4 billion in 2023. The progress of the competitive landscape will help the market valuation reach USD 231.8 billion by 2034. The last recorded size of the industry was USD 102.4 billion in 2023. The likelihood of various neurological disorders is growing with the rising senior population across the world. Along with this, many...
PR Newswire
17/07/2024

BioProcess360 Partners launch dedicated Life Sciences investment fund to grow…

Will connect innovators with investment, hands-on expertise and the leading biopharmaceutical manufacturers “The largest challenges businesses face when establishing new technologies in the bioprocessing space typically stem from a lack of access to real industry experience and knowledge required to help them navigate through critical growth challenges. Being a serial entrepreneur, I know exactly what it takes to be truly successful in this space” said Chris Major, Founding Partner,...
Nasdaq GlobeNewswire
17/07/2024

First procedure in Netherlands with NaoTrac surgical navigation robot is…

To avoid long and frustrating registration process, NaoTrac incorporates machine vision technology, and finishes the patient and instrument registrations within 30 seconds to 3 minutes. It is an open platform, and the instrument registration is performed by the robotic arm automatically, much safer and faster. To avoid long and frustrating registration process, NaoTrac incorporates machine vision technology, and finishes the patient and instrument registrations within 30 seconds to 3 minutes...
PR Newswire
17/07/2024

De Motu Cordis (DMC) announces plans for the next stage of development for…

"We are excited to build on our partnership with Catalent, one of the world's leading CDMOs, and look forward to Catalent's team supporting our ability to further advance DMC-IH1, through support for drug product manufacture and dry powder inhaler assembly," said Peter O'Neill, Chief Executive Officer, DMC. "Catalent provides DMC with a consistency of quality and manufacturing excellence in the United States to service global markets." "We are excited to build on our…
PR Newswire
17/07/2024

Orexo Q2 2024 Interim Report

Q2 2024 highlights Q2 2024 highlights Important events after the end of the ­period CEO comments in brief: Strong Zubsolv® recovery and focus on getting OX124 to the US market"I am pleased to report our Zubsolv sales grew slightly year on year, with a strong improvement from the first quarter. This is the third consecutive quarter that we have achieved a positive EBITDA, despite additional costs for a new human factor study (HF study) for OX124, increased legal expenses and a...
PR Newswire
17/07/2024

EssilorLuxottica signs an agreement to acquire a majority stake in Heidelberg…

EssilorLuxottica signs an agreement to acquire a majority stake in Heidelberg Engineering and continues to make moves in the med-tech spaceThe transaction will create growth opportunities for Heidelberg Engineering and confirms EssilorLuxottica's commitment to further elevating industry standards and enhancing patients' quality careParis, France and Heidelberg, Germany (17 July 2024 – 8 am CEST) – EssilorLuxottica and Heidelberg Engineering announced today they entered into an...
Nasdaq GlobeNewswire
17/07/2024

EssilorLuxottica to Acquire Supreme® from VF Corporation

EssilorLuxottica to AcquireSupreme®from VF Corporation Paris, France and Denver, CO (17 July 2024 – 8am CEST) -EssilorLuxottica, a global leader in the optical industry, and VF Corporation (NYSE: VFC), a global leader in branded lifestyle apparel, footwear and accessories, today announced that they have entered into a definitive agreement for EssilorLuxottica to acquire theSupreme ® brand from VF for $1.5 billion in cash. Francesco Milleri, Chairman and Chief...
Nasdaq GlobeNewswire
17/07/2024

ONWARD® Medical Publishes Annual Sustainability Summary

Company strengthens sustainability practices prior to commercialization hereand on the Company's website in the Investors section ( https://ir.onwd.com/esg-information ). EcoVadis, the world's largest provider of business sustainability ratings, rated ONWARD Medical in the top 40% in the industry for its sustainability performance. The EcoVadis assessment evaluates 20+ sustainability criteria across four core themes: Environment, Labor & Human Rights, Ethics, and Sustainable...
Nasdaq GlobeNewswire
17/07/2024

Inside information: Phase III ARANOTE trial of darolutamide in combination with…

ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 17 JULY 2024 at 8.30 EEST Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint Orion and Bayer's Phase III ARANOTE trial meets primary endpoint, significantly increasing radiological progression-free survival (rPFS) with darolutamide + androgen deprivation therapy (ADT) compared to...
Nasdaq GlobeNewswire
17/07/2024

[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I…

After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001) 1 Pharmacokinetic data supports a once-daily oral dosing regimen for CT-996 1 The safety and tolerability profile was consistent with other oral GLP-1 receptor agonists and no unexpected safety signals were observed 1 Basel, 17 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from two arms of an ongoing...
Nasdaq GlobeNewswire
17/07/2024

Orexo shares new information on OX124, a high-dose naloxone rescue medication in…

The type of technical data required by FDA has already been generated from our pilot scale manufacturing and the data were included in the NDA. Orexo´s assessment is that the submitted data support approval however, FDA does not agree and has requested data from the established commercial scale manufacturing. The type of technical data required by FDA has already been generated from our pilot scale manufacturing and the data were included in the NDA. Orexo´s assessment is that the submitted...
PR Newswire
16/07/2024

Contact and Intraocular Lens Market Expected to Reach US$ 22.9 Billion by 2034…

This development of the industry will likely project the advancement path at a moderate CAGR of 6.4% through the forecasted period. Influenced by various driving forces, the market will create lucrative prospects for key players. The growing prevalence related to eyesight issues and cataracts has leveraged the demand for contact lenses. With the elevated demand for treatments for eyesight correction, leading manufacturers can expect better prospects in the forecasted period. In the...
PR Newswire
16/07/2024

Corneal Transplant Market to Reach an Estimated US$ 805.8 Million by 2034 with a…

Innovations in corneal transplant procedures, such as Descemet's Membrane Endothelial Keratoplasty (DMEK) and Descemet's Stripping Endothelial Keratoplasty (DSEK), have improved outcomes and reduced recovery times, making these surgeries more attractive to patients and practitioners. Innovations in corneal transplant procedures, such as Descemet's Membrane Endothelial Keratoplasty (DMEK) and Descemet's Stripping Endothelial Keratoplasty (DSEK), have improved outcomes and reduced recovery…
PR Newswire
16/07/2024

Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug…

In this free webinar, the expert speakers will provide an introduction to free selection on different target types ranging from enzymes to receptors and highlight the unique advantages or features for the application of DELs on these targets. They will also describe various DEL platforms that have been developed and how they can be utilized to achieve success in the drug discovery process. In this free webinar, the expert speakers will provide an introduction to free selection on different...
PR Newswire
16/07/2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

AggregatedpresentationbydayandbymarketPurchases of own shares from July 8th to 12th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1108/07/2024FR00102591506 650111,0282XPARIPSEN549300M6SGDPB4Z94P11...
Nasdaq GlobeNewswire
16/07/2024

Groupe Casino : Bilan du contrat de liquidité au 30 juin 2024

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 3 957 404,44 € Siège social : 1, Cours Antoine Guichard 42000 SAINT-ETIENNE 554 501 171 R.C.S. SAINT-ETIENNECommuniqué établissant le bilan semestriel du contrat de liquidité de la sociétéCASINO, GUICHARD-PERRACHON Au titre du contrat de liquidité confié par la société Casino, Guichard-Perrachon à Rothschild Martin Maurel, lequel est suspendu depuis le 11 juin 2024 1, les moyens suivants figuraient au compte de...
Nasdaq GlobeNewswire
16/07/2024

RAMSAY SANTE :Refinancing of Senior Debt Facilities

PRESS RELEASE Paris, 16 July 2024 Refinancing of Senior Debt FacilitiesRamsay Santé has started today the Amend & Extend process for the refinancing of its €1,650m Senior Facilities, including €100m RCF and €100m Capex lines, to proactively extend its upcoming 2026-2027 debt maturities. The closing of this Amend & Extend process is subject to market conditions. Such refinancing would enable Ramsay Santé to further support the implementation of its key initiatives as part...
Nasdaq GlobeNewswire
16/07/2024

VIRBAC: exceptional first-half momentum (+16.2% at constant exchange rates)…

KEY FIGURESRevenue in first half of 2024 €703.1MGrowth at constant exchange ratesand scope 1 +11.3%including companion animals +15.1%farm animals +7.0%Growth at constantexchange rates 2 +16.2% Overallchange +15.2% 1 growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial...
Nasdaq GlobeNewswire
16/07/2024

Medical Specialty Bags Market Projected to Exceed US$ 14.3 Billion by 2032…

Current market trends for medical specialty bags point to a change in emphasis toward creating biobased and sustainable materials to lower carbon emissions and enhance patient safety. Continuous research and development in bag design and material, such as adding safety features and anti-microbial sealants, helps improve durability and reduce contamination and leakage. Current market trends for medical specialty bags point to a change in emphasis toward creating biobased and sustainable...
PR Newswire
16/07/2024

Membrane Microfiltration Market Set to Surge at 4.7% CAGR, projected to Reach…

Different companies have installed large wastewater treatment plants, as per the guidelines of other countries' governments. Due to strict laws and regulations related to wastewater treatment, the demand for filtration membranes has been increasing, which is a major driving force for the market. Different companies have installed large wastewater treatment plants, as per the guidelines of other countries' governments. Due to strict laws and regulations related to wastewater treatment, the...
PR Newswire
16/07/2024

Radiation Detection, Monitoring, and Safety Market: $4.4 Billion by 2029, CAGR…

Browse in-depth TOC on "Radiation Detection, Monitoring, and Safety Market" Browse in-depth TOC on "Radiation Detection, Monitoring, and Safety Market" 364 - Tables44 - Figures307 - Pages Product Segmentation and Dominance The radiation detection, monitoring, and safety market is categorized into radiation detection and monitoring products and radiation safety products. In 2023, the radiation detection and monitoring products segment held the largest market share,...
PR Newswire
16/07/2024

Duchenne Muscular Dystrophy Market on Track to Surpass US$ 7.4 Billion by 2034…

Owing to the surge in different demand drivers, the competitive landscape will navigate through different prospective chances, enabling the industry to reach USD 7.4 billion by 2034. The sector was valued at USD 2.2 billion in 2023. Owing to the surge in different demand drivers, the competitive landscape will navigate through different prospective chances, enabling the industryto reachUSD 7.4 billion by 2034. The sector was valued at USD 2.2 billion in 2023. The progress of the...
PR Newswire
16/07/2024
Altri  Comunicati